MacroGenics Announces Phase 1 MGC026 Delivers 27% Response Rate In SCCHN, Showing Durable Tumor Activity And Advancing Toward Front-Line Pembrolizumab Combination Trial

Benzinga

2026.10.23 13:24 (GMT+0)

Открыть на Benzinga